Radiation Therapy Oncology Group

Radiation Therapy Oncology Group
Name	Radiation Therapy Oncology Group
Abbreviation	RTOG
Formation	1968
Founder	National Cancer Institute
Type	Consortium
Headquarters	Philadelphia
Region served	United States
Parent organization	National Institutes of Health

Radiation Therapy Oncology Group

The Radiation Therapy Oncology Group was a cooperative clinical trials consortium founded in 1968 under National Cancer Institute sponsorship to evaluate radiation therapy and combined-modality treatments for cancer. It coordinated multicenter trials involving academic centers, community hospitals, and research institutions such as Memorial Sloan Kettering Cancer Center, Mayo Clinic, MD Anderson Cancer Center, and Johns Hopkins Hospital to refine protocols for malignancies including glioma, lung cancer, breast cancer, prostate cancer, and head and neck cancer. The group’s trials influenced standards promulgated by organizations like the American Society for Radiation Oncology, American College of Radiology, and the European Society for Radiotherapy and Oncology.

History

RTOG’s origin traces to collaborative efforts among investigators at University of Pennsylvania, Yale School of Medicine, Stanford University School of Medicine, and Columbia University Irving Medical Center to standardize radiation techniques and endpoints. In the 1970s and 1980s RTOG conducted landmark randomized trials with participation from Duke University School of Medicine, Northwestern University Feinberg School of Medicine, and University of California, San Francisco that compared fractionation schedules and combined radiation with chemotherapy agents such as those developed by Bristol-Myers Squibb and Eli Lilly and Company. Trials in the 1990s incorporated advances from researchers at Harvard Medical School, University of Michigan, and Memorial Sloan Kettering to test concurrent chemoradiation regimens influenced by findings from groups like Eastern Cooperative Oncology Group and Children's Oncology Group. Administrative and statistical leadership involved staff from Columbia University, University of Texas MD Anderson Cancer Center, and the Fred Hutchinson Cancer Research Center. By the 2000s technological adoption—driven by collaborators such as Philips, Varian Medical Systems, and Siemens Healthineers—enabled trials using three-dimensional conformal radiotherapy and intensity-modulated radiotherapy pioneered at centers like UCLA and Washington University School of Medicine. Regulatory interactions included the Food and Drug Administration and policy dialogue with Centers for Medicare & Medicaid Services.

Mission and Organization

The group’s mission emphasized improving patient outcomes through randomized trials, translational research, and quality assurance across institutions including Brigham and Women's Hospital, Vanderbilt University Medical Center, and University of Chicago Medical Center. Governance featured an executive committee with investigators from University of WisconsinMadison, Ohio State University Wexner Medical Center, and University of Pittsburgh Medical Center, protocol chairs drawn from Mount Sinai Health System, and a central statistical center at institutions like Thomas Jefferson University. RTOG’s structure included disease-specific committees (e.g., thoracic oncology, neuro-oncology, gynecologic oncology—with clinical sites such as Robert Wood Johnson University Hospital and University of Colorado Anschutz Medical Campus), a radiation quality assurance office collaborating with Imaging and Radiation Oncology Core, and data management supported by centers like Moffitt Cancer Center.

Clinical Trials and Research Contributions

RTOG conducted pivotal trials impacting standards for glioblastoma, where studies led by investigators from Massachusetts General Hospital and Duke University established combined-modality approaches alongside trials in non-small cell lung cancer that influenced practice at University of Pennsylvania Health System and Cleveland Clinic. Key protocols assessed dose escalation, altered fractionation, radiosensitizers, and organ-preserving strategies paralleling advances from National Surgical Adjuvant Breast and Bowel Project and Gynecologic Oncology Group. RTOG’s data sets supported biomarker and genomics work with partners at Broad Institute, The Cancer Genome Atlas, and Dana-Farber Cancer Institute, enabling correlative science in hypoxia imaging studied at Oregon Health & Science University and radiomics research with teams at University of Toronto. Trials such as those addressing postoperative radiation for head and neck squamous cell carcinoma and adjuvant therapy for breast carcinoma altered nodal and dose guidelines cited in consensus statements by National Comprehensive Cancer Network panels and influenced staging considerations endorsed by the American Joint Committee on Cancer.

Collaborations and Networks

RTOG partnered with cooperative groups including Cancer and Leukemia Group B, Southwest Oncology Group, Children's Oncology Group, and international consortia like European Organisation for Research and Treatment of Cancer. Industry collaborations included device and software firms such as Varian Medical Systems, Elekta, and pharmaceutical companies including Pfizer, Merck & Co., and Novartis for investigational agents. RTOG integrated with quality assurance networks like Radiological Physics Center and imaging cores at Washington University School of Medicine and maintained ties to professional societies including American Society of Clinical Oncology and Society for Neuro-Oncology. Educational outreach and guidelines dissemination involved institutions such as Johns Hopkins University, University of California San Diego, and University of North Carolina.

Impact on Radiation Oncology Practice

The group’s randomized evidence informed guidelines used by clinicians at Massachusetts General Hospital Cancer Center, Memorial Sloan Kettering Cancer Center, and community systems like Kaiser Permanente. Outcomes data influenced reimbursement policy deliberations at Centers for Medicare & Medicaid Services and practice parameters by American College of Radiology. RTOG reports advanced technologies—three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, stereotactic body radiotherapy—validated in trials at Stanford University Medical Center and University of Texas Southwestern Medical Center—and informed training curricula at University of Michigan Medical School and Yale School of Medicine residency programs.

Legacy and Evolution into NRG Oncology

In 2014 RTOG merged with Gynecologic Oncology Group and National Surgical Adjuvant Breast and Bowel Project to form NRG Oncology, consolidating expertise from centers such as Memorial Sloan Kettering, MD Anderson Cancer Center, and Dana-Farber Cancer Institute. The legacy includes large trial databases used by researchers at Broad Institute, The Cancer Genome Atlas, and Fred Hutchinson Cancer Research Center for secondary analyses, and ongoing influence within cooperative group research frameworks including Alliance for Clinical Trials in Oncology and EORTC. Key investigators who led RTOG protocols held appointments at Harvard Medical School, Perelman School of Medicine at the University of Pennsylvania, and Columbia University Irving Medical Center, ensuring continuity of trial methodology, quality assurance, and multisite collaboration into the NRG Oncology era.

Category:Cancer research organizations